Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases
Status:
Completed
Trial end date:
2020-10-05
Target enrollment:
Participant gender:
Summary
This is an open-label, single centre, Phase I study to determine the brain exposure of
[11C]osimertinib in patients with EGFRm NSCLC with brain metastases.